search button
Open Access

miR‑629 targets FOXO3 to promote cell apoptosis in gastric cancer

  • Authors:
    • Ming Li
    • Yingxin Wang
    • Xia Liu
    • Zhenduo Zhang
    • Liwei Wang
    • Yong Li

  • View Affiliations

  • Published online on: November 6, 2019     https://doi.org/10.3892/etm.2019.8168
  • Pages: 294-300

  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gastric cancer (GC) is one of the most aggressive types of human tumor worldwide, and the 5‑year survival rate is less than 25%. The transcriptional factor, forkhead box O3 (FOXO3), is regulated by various micro (mi)RNAs and has been reported to be associated with multiple regulatory signaling pathways involved in tumor development. The current study therefore assessed the impact of miR‑629 and FOXO3 on gastric cancer. Reverse transcription‑quantitative polymerase chain reaction and western blotting were performed to assess the expression of mRNA and protein, respectively. Additionally, the cell proliferation and apoptosis rate were determined via an MTT assay and flow cytometry, respectively. The online database TargetScan predicted that FOXO3 was a target of miR‑629. A luciferase reporter assay was also performed to verify that FOXO3 was the direct target of miR‑629. The results demonstrated that miR‑629 and FOXO3 was upregulated and downregulated in GC tissue, respectively. Furthermore, following transfection with a miR‑629 inhibitor, SGC‑7901, cell proliferation and apoptosis rate were inhibited and promoted when compared with the control group, respectively. Moreover, after the treatment with SGC‑7901, the expression of FOXO3, Bax, Caspase 3 was upregulated, and Bcl‑2 was downregulated. Furthermore, the luciferase reporter assay revealed that FOXO3 was the target of miR‑629. The results demonstrated that miR‑629 and FOXO3 serve vital roles in the development of gastric cancer and may be a future therapeutic target.
View Figures
View References

Related Articles

Journal Cover

January-2020
Volume 19 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.7
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Li M, Wang Y, Liu X, Zhang Z, Wang L and Li Y: miR‑629 targets FOXO3 to promote cell apoptosis in gastric cancer. Exp Ther Med 19: 294-300, 2020
APA
Li, M., Wang, Y., Liu, X., Zhang, Z., Wang, L., & Li, Y. (2020). miR‑629 targets FOXO3 to promote cell apoptosis in gastric cancer. Experimental and Therapeutic Medicine, 19, 294-300. https://doi.org/10.3892/etm.2019.8168
MLA
Li, M., Wang, Y., Liu, X., Zhang, Z., Wang, L., Li, Y."miR‑629 targets FOXO3 to promote cell apoptosis in gastric cancer". Experimental and Therapeutic Medicine 19.1 (2020): 294-300.
Chicago
Li, M., Wang, Y., Liu, X., Zhang, Z., Wang, L., Li, Y."miR‑629 targets FOXO3 to promote cell apoptosis in gastric cancer". Experimental and Therapeutic Medicine 19, no. 1 (2020): 294-300. https://doi.org/10.3892/etm.2019.8168